Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 56

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 56
---
 investing activities 
     -  
     - 
  
    Net cash flows from financing activities 
    $-  
    $45,000 
  
    Net increase (decrease) in cash 
    $(1,063,041) 
    $(35,953)

Net Cash Flows From Operating
Activities:

Net cash used in operating
activities during the three months ended March 31, 2025 was $1,063,041, as compared to net cash used in operating activities of $65,165.
The increase in net cash used in operating activities was primarily related to the changes in our net loss.

Net Cash Flows From Investing
Activities:

No net cash was provided by
or used in investing activities for the three months ended March 31, 2025 and 2024.

Net Cash Flows From Financing Activities:

Net cash provided in financing
activities during the three months ended March 31, 2025 was $0, as compared to net cash provided in financing activities of $45,000. The
decrease in net cash provided was primarily related to no new financing being provided in the current period compared to the prior period.

Off-balance sheet financing arrangements

We have no obligations, assets
or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships
with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established
for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Business Development Activities

The Company initiated
business development activities in the Asian region in 2021. The Company has a strong strategic interest in accelerating the drug
development and potential commercialization efforts of JOTROL in this market. Our Chairman & CEO, presented in person, our
company’s status and pipeline at the BIOHK 2023 conference in Hong Kong in September of 2023. The presentation led to several
follow-on meetings, and we have recently agreed to service agreements in the areas of business development, CMC (Chemistry,
Manufacturing, and Controls), regulatory affairs and clinical trial management. The Asian market is very large and hard to penetrate for a small company and we
believe that our strategy with these agreements is cost effective and have the possibility to accelerate an out-licensing deal